LONZA GRP N (LO3 DU) stock market data APIs
€575.1641
-1.32(-0.2%)
as of February 25, 2026
Try our APIs with
free plan!
LONZA GRP N Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for LO3.DU.
Prev. Close
575.1641
Open
573.8409
High
575.3256
Low
568.1388
52 wk Range
288.1532-637.262
Market Cap
53 581 M
Dividends (Yield)
0.0137
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get LONZA GRP N data using free add-ons & libraries
Get LONZA GRP N Fundamental Data
LONZA GRP N Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-01-28
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
LONZA GRP N News
New
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process,...
Global Cell and Gene Therapy Manufacturing QC Market Forecast to Achieve USD 2.01 Billion by 2031: Automation and Digitalization Revolutionizing the Landscape
Company Logo Features Profiles of Key Players Bio-Techne, bioMerieux, Roche, Lonza Group, Miltenyi Biotec India and More Cell and Gene Therapy Manufacturing QC MarketCell and Gene Therapy Manufactur...
Lonza Group AG's (VTX:LONN) Intrinsic Value Is Potentially 26% Below Its Share Price
Key Insights Lonza Group's estimated fair value is CHF412 based on 2 Stage Free Cash Flow to Equity Lonza Group is estimated to be 34% overvalued based on current share price of CHF554 The CHF677 ana...
Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
